Mangoceuticals, Inc. (NASDAQ: MGRX), a company focused on developing, marketing, and selling a variety of men’s wellness products and services via a secure telemedicine platform, is pleased to announce that it has entered into an exclusive Master Distribution Agreement with Propre Energie, Inc., the developer of skincare brand Dermytol®, a clinically proven treatment designed to improve skin tone and reduce hyperpigmentation.
Dermytol® is an advanced, plant-based formula developed to address dark spots, uneven skin tone, acne scars, and other pigmentation concerns. Unlike traditional skin treatments that may cause irritation or long-term damage, Dermytol® utilizes a proprietary blend of clinically validated ingredients, including canola phenolic acid, Camellia sinensis tea extract, evening primrose, and aloe vera. The patented formulation harnesses the melanin-reducing properties of canola extract, providing a safer and more stable alternative to conventional ingredients like hydroquinone and kojic acid.
The efficacy of Dermytol® as a safe and effective skincare treatment was demonstrated in vitro, where it was tested against Kojic acid—a widely used skin lightening agent derived from fungi. At medium and high concentrations, Dermytol® was found to be more effective at reducing melanin production while being significantly less damaging to skin cells than Kojic acid. According to the study, this would make Dermytol® a superior option for individuals seeking a clinically backed solution for hyperpigmentation and overall skin health.
The global skincare market is projected to reach approximately $218 billion by 2029, growing at a compound annual growth rate (CAGR) of 3.61% from 2025 to 2029. Within this expansive market, the plant-based skincare segment is experiencing significant growth. The global plant-based skincare products market, valued at $789.75 million in 2023, is expected to grow to $1.62 billion by 2033, reflecting a robust CAGR of 7.5% over the next decade. This surge is driven by consumer demand for natural, science-backed skincare solutions that offer visible results without compromising skin health.
Consumers are increasingly prioritizing products that promote healthier, more sustainable options, driving the market for non-retinol skincare solutions. Dermytol®️ is poised to meet this demand with its innovative, clinically proven formulations, addressing a significant gap in the market for safe and effective solutions for hyperpigmentation, dark spots, and uneven skin tone
Jacob Cohen, CEO of Mangoceuticals, Inc., expressed enthusiasm for the partnership, stating: “We are thrilled to add Dermytol®️ to our growing portfolio of high-performance wellness products. The demand for effective, natural skincare solutions is on the rise, and this collaboration allows us to bring a scientifically advanced product to market that aligns perfectly with our mission of delivering high-quality health and wellness solutions.”
Peter Polimeneas, CEO of Propre Energie Inc., added: “This agreement is a significant milestone for Dermytol®️ as we expand into new markets with the support of a strong and experienced partner. Mangoceuticals’ expertise in digital marketing and e-commerce, combined with their dedication to quality, makes them the ideal distributor for our brand.”
Through this agreement, Mangoceuticals secures exclusive rights to market, sell, and distribute Dermytol® across North and South America. The product will be available in both patch and cream formulations, offering versatile treatment options for consumers seeking to improve their skin’s radiance and overall health. Mangoceuticals aims to leverage its robust marketing and distribution infrastructure to accelerate Dermytol®’s penetration in key markets.
About Propre Energie, Inc.
Propre Energie Inc. is a Quebec-based company specializing in plant-based, non-retinol skincare solutions under the Dermytol®️ brand. With a focus on research and innovation, Propre Energie is dedicated to developing clinically proven, safe, and effective skincare products for individuals seeking healthier skin.
About MangoRx
MangoRx is focused on developing a variety of men’s health and wellness products and services via a secure telemedicine platform. To date, the Company has identified men’s wellness telemedicine services and products as a growing sector and especially related to the area of erectile dysfunction (ED), hair growth, hormone replacement therapies, and weight management. Interested consumers can use MangoRx’s telemedicine platform for a smooth experience. Prescription requests will be reviewed by a physician and, if approved, fulfilled and discreetly shipped through MangoRx’s partner compounding pharmacy and right to the patient’s doorstep.
No comments:
Post a Comment